Study looks at using the immune system to reduce prostate cancer risk

	Tweet

Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.

The study was done in mice and would need further validation and extensive testing in the lab before being available for humans. But the results are promising for people with a strong family history of cancer or known cancer genes.

Typically, vaccines are based on specific antigens and trigger immunity for a specific pathogen. This is more challenging for cancer as the best lymphocytes that generate immunity to cancer are eliminated during development. In this new study, researchers sought to rescue these key lymphocytes – called high affinity cancer-reactive T cells – during their development. 

The study appears online this week in the Proceedings of the National Academy of Sciences.

The researchers first showed that T cells involved in prostate cancer are deleted because of a gene called lymphotoxin alpha. When the mice lacked lymphotoxin, these T cells came back. These mice become more resistant to prostate cancer. This result suggests that lymphotoxin can be a good target for immune prevention.

Next, the researchers injected a protein targeting lymphotoxin into cancer-susceptible mice. Without treatment, all of these mice will develop prostate cancer, and typically by age 6 months half of them will have metastatic cancer that has spread to distant organs. Although the treated mice still developed tumors, none developed metastases after 30 weeks.

“It appears that the rescued T cells delay tumor formation. It may not be that this approach can prevent cancer altogether, but it can delay the process and slow the aggressive growth and spread of cancer,” says study author Pan Zheng, M.D., Ph.D., associate professor of surgery and pathology at the U-M Medical School.

While this study looked specifically at mice with prostate cancer, the approach has potential for other types of cancer.

“There is a certain population with a high likelihood of getting cancer, and we need better strategies to minimize their risk. This approach may be translated into clinical care for those patients,” Zheng says.

Prostate cancer statistics: 192,280 Americans will be diagnosed with prostate cancer this year and 27,360 will die from the disease, according to the American Cancer Society

Additional authors: Penghui Zhou, Beth A. McNally, Lizhong Wang, Yang Liu, from U-M; Xiafeng Fang from the Chinese Academy of Science; and Ping Yu, Mingzhao Zhu, Yang-Xin Fu, from the University of Chicago School of Medicine

Funding: National Institutes of Health, Department of Defense Prostate Cancer Research Program

Reference: Proceedings of the National Academy of Sciences, doi: 10.1073/pnas.0905707106

Media contact: Nicole Fawcett
E-mail:
Phone: 734-764-2220

University of Michigan Health System
1500 E. Medical Center Drive Ann Arbor, MI 48109 734-936-4000

RELATED STORIES:
Men, Don’t Skip Your Prostate Cancer Treatment Appointments!   Novel association between Parkinson’s disease and prostate cancer   Prostate Cancer: Watchful Wait or Vaccinate?   Folate may alter risk of prostate cancer progression   Swiss study finds income affects prostate cancer patients’ survival   Heavy men fare poorly with prostate cancer   Early prostate cancer detection, screening: No benefit for men with low baseline PSA value   Discovery of a new virus in prostate tumors   Racial disparity seen in prostate cancer treatment   Genetic factors key to prostate cancer death risk   Smaller prostate size, more aggressive cancer   Carcinoma of the Prostate Treatment   Vitamin E may raise prostate cancer risk   Brisk walking may help men with prostate cancer, UCSF study finds   Why a common treatment for prostate cancer ultimately fails   Prostate cancer surgery more costly for obese men   Possible link found between x-rays and prostate cancer   Researchers Uncover How Prostate Cancer Cells Defy Death   Prostate cancer patients disease free after 5 years likely to be disease free after 10 years   Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients   Study finds prostate screening cuts cancer deaths   Statins don’t protect against cancer: study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]